全文获取类型
收费全文 | 625篇 |
免费 | 26篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 17篇 |
妇产科学 | 11篇 |
基础医学 | 44篇 |
口腔科学 | 8篇 |
临床医学 | 63篇 |
内科学 | 141篇 |
皮肤病学 | 9篇 |
神经病学 | 37篇 |
特种医学 | 26篇 |
外科学 | 161篇 |
综合类 | 10篇 |
预防医学 | 50篇 |
眼科学 | 8篇 |
药学 | 11篇 |
中国医学 | 2篇 |
肿瘤学 | 53篇 |
出版年
2023年 | 6篇 |
2022年 | 13篇 |
2021年 | 23篇 |
2020年 | 10篇 |
2019年 | 23篇 |
2018年 | 17篇 |
2017年 | 6篇 |
2016年 | 11篇 |
2015年 | 25篇 |
2014年 | 24篇 |
2013年 | 25篇 |
2012年 | 43篇 |
2011年 | 56篇 |
2010年 | 20篇 |
2009年 | 27篇 |
2008年 | 34篇 |
2007年 | 43篇 |
2006年 | 30篇 |
2005年 | 39篇 |
2004年 | 22篇 |
2003年 | 27篇 |
2002年 | 21篇 |
2001年 | 23篇 |
2000年 | 17篇 |
1999年 | 17篇 |
1998年 | 5篇 |
1997年 | 7篇 |
1996年 | 5篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1976年 | 2篇 |
1973年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有656条查询结果,搜索用时 15 毫秒
81.
Jai Kumar Roha Saeed Memon Izza Shahid Tehlil Rizwan Maryam Zaman Ritesh G. Menezes Sarwan Kumar Tariq Jamal Siddiqi Muhammad Shariq Usman 《Digestive and liver disease》2021,53(1):44-51
BackgroundThe efficacy of antidiabetic agents for the treatment of non-alcoholic fatty liver disease (NAFLD) remains unclear.AimTo conduct a meta-analysis to study the efficacy of pioglitazone and three novel anti-diabetic agents: glucagon-like peptide-1 (GLP-1) agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and dipeptidyl-peptidase-4 (DPP4) inhibitors in treating NAFLD.MethodsOnline databases were searched in May 2020 for randomized clinical trials. Results from random-effects meta-analysis are presented as weighted mean differences (WMDs) or standard mean differences (SMDs) and corresponding 95% confidence intervals (CIs).ResultsTwenty-six studies (n=946 NAFLD patients) were included. Reductions in ALT were seen with all four drugs: pioglitazone (MD -38.41, p<0.001), SGLT2 inhibitors (MD -16.17, p<0.001), GLP-1 agonists (MD -27.98, p=0.04) and DPP-4 inhibitors (MD -7.41, p<0.001). Pioglitazone (SMD -1.01; p<0.001) and GLP-1 agonists (SMD -2.53, p=0.03) also demonstrated significant improvements in liver steatosis. SGLT2 inhibitors (SMD -4.64, p=0.06) and DPP-4 (SMD -2.49, p=0.06) inhibitors trended towards reduced steatosis; however, these results were non-significant.ConclusionPioglitazone demonstrates significant improvements in transaminases and liver histology in both diabetic and non-diabetic NAFLD patients. Early evidence from diabetic NAFLD patients suggests that novel antidiabetics may lead to improvements in liver enzymes and hepatic steatosis, and this should encourage further research into possible utility of these drugs in treating NAFLD. 相似文献
82.
Reyes Enciso Robert A. Danforth Emanuel S. Alexandroni Ahmed Memon James Mah 《International journal of computer assisted radiology and surgery》2006,1(2):113-116
Precise 3-dimensional localization of impacted mandibular third molars relative to the inferior dental canal (IDC) is critical to clinical management and surgical outcomes. Recently introduced dental 3-D volumetric imaging systems coupled with semi-automatic modeling techniques allows 3-D visualization of the IDC and the third-molar. Six impacted third molar sites were imaged with various 3-D volumetric imaging systems (NewTom 9000, Morita Accuitomo and Hitachi Mercuray). The spatial relationship of six impacted third-molars were visualized using imaging data obtained from these units. An interactive virtual model of a proposed third molar surgical site including the third molar and the inferior dental canal was developed. 相似文献
83.
84.
85.
Maria Hasan Wang Meiou Liu Yulian Sami Ullah Huy Q. Ta Liang Zhao Rafael G. Mendes Zahida P. Malik Nasir M. Ahmad Zhongfan Liu Mark H. Rümmeli 《RSC advances》2019,9(28):16057
Correction for ‘Direct chemical vapor deposition synthesis of large area single-layer brominated graphene’ by Maria Hasan et al., RSC Adv., 2019, 9, 13527–13532.In the Acknowledgements section, the attribution “the Czech Republic from ERDF “Institute of Environmental Technology – Excellent Research” (No. CZ.02.1.01/0.0/0.0/15_019/0000853), should read “the Czech Republic from ERDF OP RDE project No. CZ.02.1.01/0.0/0.0/16_019/0000853”.The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers. 相似文献
86.
87.
M. El-Haddad M. El-Sebaie R. Ahmad E. Khalil M. Shahin R. Pant M. Memon A. Al-Hebshi Y. Khafaga M. Al-Shabanah A. Allam 《Clinical oncology (Royal College of Radiologists (Great Britain))》2009,21(10):775-780
AimsAggressive fibromatosis is a locally aggressive infiltrative low-grade tumour, although pathologically benign, and it does not metastasise, yet it can cause serious local distressing symptoms by virtue of local destruction and impairment of local function. The aim of this study was to emphasise the role of radiotherapy and adequate surgery in the treatment of fibromatosis in patients presenting with newly diagnosed or recurrent disease and to analyse our treatment results over 15 years for this rare tumour type.Materials and methodsFifty-four patients with confirmed diagnosis of aggressive fibromatosis treated at King Faisal Specialist Hospital between 1990 and 2006 were identified from our local cancer registry. Forty-seven patients had surgery: complete resection (R0) in 20 patients, incomplete surgery (R1/2) in 27 patients, and seven patients had biopsy only. Forty-five patients were treated with radiotherapy: 38 patients were treated with postoperative radiotherapy, three patients were treated with preoperative radiotherapy and four patients had radiotherapy as the only treatment. The radiotherapy dose ranged between 45 and 60 Gy (median 50.4 Gy). Three patients did not receive any form of treatment apart from biopsy, but were still included in the final analysis.ResultsFifty-two per cent (28/54 patients) of our patient population had tumour recurrence when first presented to King Faisal Specialist Hospital. The median age was 29.5 years (range 2–63 years). The most common site of involvement was the extremities (28 patients). Among the 54 patients (with primary and recurrent presentation) there were 10 local recurrences, all of which were within the original primary site. The 5-year progression-free survival and overall survival rates for the whole group were 75 and 95%, respectively. Univariate and multivariate Cox regression analysis showed that the depth of invasion significantly affected progression-free survival.ConclusionAggressive fibromatosis is effectively treated with surgery and postoperative radiotherapy. Patients first presenting with tumour recurrence may still have local tumour control comparable with newly diagnosed patients. 相似文献
88.
al-Wakeel JS; Mitwalli AH; Huraib S; al-Mohaya S; Abu-Aisha H; Chaudhary AR; al-Majed SA; Memon N 《Nephrology, dialysis, transplantation》1997,12(7):1420-1424
High serum fluoride (F-) in patients with chronic renal failure (CRF) and
end-stage renal disease (ESRD) is associated with risk of renal
osteodystrophy and other bone changes. This study was done to determine F-
in normal healthy controls and patients with ESRD on haemodialysis (HD) or
peritoneal dialysis (PD). Seventeen healthy controls (12 males, 5 females)
and 39 ESRD patients on dialysis (17 males, 22 females) were recruited in
the study in a community with 47.4 +/- 3.28 microM/l (range 44-51 microM/l)
of F- content in drinking water. Control subjects showed a mean serum F-
concentration of 1.08 +/- 0.350 microM/l. Males in control group showed
slightly higher F- levels (1.15 +/- 0.334, range 0.55-1.9 microM/l) than
females (0.92 +/- 0.370, range 0.6-1.5 microM/l). Mean serum F-
concentration did not correlate significantly with age and sex among
control subjects, whereas such correlation was observed in patients with
ESRD on dialysis. Mean serum F- concentration was significantly higher in
patients on dialysis (2.67 +/- 1.09, range 0.8-5.2 microM/l) than normal
controls. When grouped according to sex, the mean serum F- concentration in
males (3.05 +/- 1.04, range 1.8-5.2 microM/l) was significantly higher than
females (2.38 +/- 1.08, range 0.8-5.2 microM/l). When patients were grouped
according to age, it was observed that F- concentration was significantly
higher in patients with age groups 21-70 (2.86 +/- 1.05) than those with
age group 13-20 years (1.42 +/- 0.531). Thus F- concentration correlated
with age and sex, being higher in males and above 20 years. Despite
appreciable clearance of F- (39-90%) across the peritoneum, patients on
CAPD showed higher serum F- concentration than those on HD (3.1 +/- 1.97 vs
2.5 +/- 1.137 microM/l). Of the total 39 patients on dialysis 39% had their
serum F- concentration above 3.0 microM/l, posing the risk of renal
osteodystrophy.
相似文献
89.
90.